The Effects of SGLT 2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70232 ↗At a glance
Systematische Übersicht in Pharmacology Research & Perspectives, 2026. Written by Weena Joongpan and 5 co-authors. Institution: Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Muscle, Skeletal. Cited 3 times so far (Crossref); 80 references. The full text is freely available (open access, CC BY 4.0).
Topics: Gerontologische Pflege
Abstract (original language)
Type 2 diabetes mellitus (T2DM) and obesity are growing global health concerns, particularly in older adults who are at higher risk of sarcopenia. While sodium‐glucose cotransporter 2 (SGLT2) inhibitors show promise for glycemic control and weight loss, their effects on muscle health remain unclear. We examined the effects of SGLT2 inhibitors on body weight, fat mass, and muscle mass in T2DM patients. We systematically searched the PubMed, Embase, Scopus, and Cochrane databases for relevant randomized controlled trials (RCTs). Three reviewers screened the studies, and two extracted data and assessed their quality. R software was used to evaluate heterogeneity via Cochran's Q and I 2 statistics. Eight RCTs ( n = 541) were included. SGLT2 inhibitors significantly reduced body weight (standardized mean difference (SMD) = −0.85, p < 0.001; I 2 = 0%) and fat mass (SMD = −0.53, p < 0.001; I 2 = 51.1%). A small reduction in muscle mass was observed (SMD = −0.35, p < 0.001; I 2 = 22.9%), though substantially smaller than fat loss. Subgroup analysis confirmed that fat mass was reduced with dapagliflozin/ipragliflozin (SMD = −0.67, p < 0.001; I 2 = 26.4%) and empagliflozin (SMD = −0.53, p < 0.001; I 2 = 66.4%). SGLT2 inhibitors effectively reduce body weight primarily through fat loss in older adults. Although muscle mass declined modestly, the predominance of fat loss suggests weight reduction occurs through favorable metabolic changes. Given the slight muscle mass changes and study heterogeneity, careful monitoring in older adults is warranted, and further studies in diverse populations are needed.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
- Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
- Department of Mathematics, Faculty of Science, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
- Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.
ORCID profiles: Nutthapoom Pathomthongtaweechai
Cite
APA
Joongpan, W., Boonmuen, N., Sinchai, P., Lapmanee, S., Klamsakul, N., & Pathomthongtaweechai, N. (2026). The Effects of SGLT 2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70232
Vancouver
Joongpan W, Boonmuen N, Sinchai P, Lapmanee S, Klamsakul N, Pathomthongtaweechai N. The Effects of SGLT 2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70232
BibTeX
@article{Joongpan2026,
author = {Joongpan, Weena and Boonmuen, Nittaya and Sinchai, Pimthong and Lapmanee, Sarawut and Klamsakul, Natawat and Pathomthongtaweechai, Nutthapoom},
title = {The Effects of SGLT 2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70232}
}
EUVIMED